| [1] |
Zhao Q, Dai H, Liu X, et al. Helper T cells in idiopathic membranous nephropathy[J]. Front Immunol, 2021, 12(1):665629. doi:10.3389/fimmu.2021.665629.
|
| [2] |
Dantas M, Silva L B B, Pontes B T M, et al. Membranous nephropathy[J]. J Bras Nefrol, 2023, 45(2):229-243. doi:10.1590/2175-8239-JBN-2023-0046en.
|
| [3] |
Lu Z, Liu W, Gao H, et al. Traditional Chinese Medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy:a systematic review and meta-analysis[J]. PLoS One, 2021, 16(5):e0251131. doi:10.1371/journal.pone.0251131.
|
| [4] |
Huang X, Shen Q K, Guo H Y, et al. Pharmacological overview of hederagenin and its derivatives[J]. RSC Med Chem, 2023, 14(10):1858-1884. doi:10.1039/d3md00296a.
|
| [5] |
Jia J, Xu L H, Deng C, et al. Hederagenin ameliorates renal fibrosis in chronic kidney disease through blocking ISG15 regulated JAK/STAT signaling[J]. Int Immunopharmacol, 2023, 118(1):110122. doi:10.1016/j.intimp.2023.110122.
|
| [6] |
Wen X, Jiao L, Tan H. MAPK/ERK Pathway as a central regulator in vertebrate organ regeneration[J]. Int J Mol Sci, 2022, 23(3):1464. doi:10.3390/ijms23031464.
|
| [7] |
Lin Z, Wang Z, Kim Thuong V P, et al. Sanqi Qushi formula ameliorates renal injury in experimental membranous nephropathy rats by inhibiting the MEK/ERK signaling pathway[J]. J Ethnopharmacol, 2025, 348(1):119813. doi:10.1016/j.jep.2025.119813.
|
| [8] |
潘华荣, 高圣柠, 申晨卉, 等. 丹参多酚酸盐调控Nrf2/HO-1信号通路对膜性肾病大鼠氧化应激的影响[J]. 天津中医药, 2024, 41(7):922-928.
|
|
Pan H R, Gao S N, Shen C H, et al. Effect of Nrf 2/HO-1 signaling regulated by salvia miltiorrhiza polyphenols on oxidative stress in rats with membranous nephropathy[J]. Tianjin Journal of Traditional Chinese Medicine, 2024, 41(7):922-928. doi:10.11656/j.issn.1672-1519.2024.07.20.
|
| [9] |
程昌琴, 陈江勇, 徐成, 等. 基于MEK/ERK/STAT3信号通路探讨丹皮酚对糖尿病心肌病大鼠的影响[J]. 中成药, 2024, 46(12):4169-4173.
|
|
Cheng C Q, Chen J Y, Xu C, et al. To explore the effect of paeonol on diabetes cardiomyopathy rats based on MEK/ERK/STAT3 signal pathway[J]. Chinese Traditional Patent Medicine, 2024, 46(12):4169-4173. doi:10.3969/j.issn.1001-1528.2024.12.044.
|
| [10] |
Shi M, Wang Y, Zhang H, et al. Single-cell RNA sequencing shows the immune cell landscape in the kidneys of patients with idiopathic membranous nephropathy[J]. Front Immunol, 2023, 14(1):1203062. doi:10.3389/fimmu.2023.1203062.
|
| [11] |
Hoxha E, Reinhard L, Stahl R A K. Membranous nephropathy:new pathogenic mechanisms and their clinical implications[J]. Nat Rev Nephrol, 2022, 18(7):466-478. doi:10.1038/s41581-022-00564-1.
|
| [12] |
Wu L, Lai J, Ling Y, et al. A review of the current practice of diagnosis and treatment of idiopathic membranous nephropathy in China[J]. Med Sci Monit, 2021, 27(1):e930097. doi:10.12659/MSM.930097.
|
| [13] |
Xie K H, Liu X H, Jia J, et al. Hederagenin ameliorates cisplatin-induced acute kidney injury via inhibiting long non-coding RNA A330074k22Rik/Axin2/β-catenin signalling pathway[J]. Int Immunopharmacol, 2022, 112(1):109247. doi:10.1016/j.intimp.2022.109247.
|
| [14] |
邵建彬, 王霞, 徐华洲, 等. 芪苓通络方抑制TLR4/MyD88/NF-κB信号通路改善特发性膜性肾病大鼠肾损伤[J]. 中国实验方剂学杂志, 2022, 28(4):100-108.
|
|
Shao J B, Wang X, Xu H Z, et al. Qiling Tongluo Prescription improves renal injury in rats with idiopathic membranous nephropathy by inhibiting TLR4/MyD88/NF-κB signaling pathway[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28(4):100-108. doi:10.13422/j.cnki.syfjx.20220391.
|
| [15] |
Yang G, Yang W, Jiang H, et al. Hederagenin inhibits high glucose-induced fibrosis in human renal cells by suppression of NLRP3 inflammasome activation through reducing cathepsin B expression[J]. Chem Biol Drug Des, 2023, 102(6):1409-1420. doi:10.1111/cbdd.14332.
|
| [16] |
Han R Y, Tan R Z, Xu L H, et al. Activation of sclerostin inhibits Isg20-mediated aerobic glycolysis ameliorating renal fibrosis:the renoprotective mechanism of hederagenin in CKD[J]. Redox Biol, 2025, 85(1):103762. doi:10.1016/j.redox.2025.103762.
|
| [17] |
Lucas R M, Luo L, Stow J L. ERK1/2 in immune signalling[J]. Biochem Soc Trans, 2022, 50(5):1341-1352. doi:10.1042/BST20220271.
|
| [18] |
Wang X, Wang J, Zheng B, et al. Sanqi oral solution alleviates podocyte apoptosis in experimental membranous nephropathy by mediating EMT through the ERK/CK2-α/β-catenin pathway[J]. Front Pharmacol, 2025, 16(1):1503961. doi:10.3389/fphar.2025.1503961.
|
| [19] |
Livingston M J, Zhang M, Kwon S H, et al. Autophagy activates EGR1 via MAPK/ERK to induce FGF2 in renal tubular cells for fibroblast activation and fibrosis during maladaptive kidney repair[J]. Autophagy, 2024, 20(5):1032-1053. doi:10.1080/15548627.2023.2281156.
|